MHRA Requests Feedback Ahead of Brexit
The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) is conducting a survey to better understand how it can support its customers in the run up to the country’s exit from European Union.
MHRA is embarking on a major operational transformation scheme across its three expert centers: the MHRA regulatory center, the National Institute for Biological Standards and Control, and the Clinical Practice Research Datalink. This includes significant investment in the organization’s digital capabilities and infrastructure, it noted.
The survey should take about 10-15 minutes to complete, depending on how many different parts of the agency an individual deals with. All responses will be held in strict confidence and will not be passed on to the agency in a way that would allow any individual contribution to be identified, according to the survey organizers.
According to the MHRA, “understanding your needs and priorities is essential to inform our plans and will help us to strategically shape our services, investment decisions, and underlying operational processes and systems. The work we do now will underpin how we are able to meet your needs for years to come.”
The survey was designed in collaboration with PA Consulting, a consulting, technology, and innovation firm, and Woodnewton Associates, an independent strategic research agency. It closes on Wednesday September 27. To complete it, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
